Apple Vision Pro Head Display New Patent Approved: Dynamic Enhancement of "Focus Mode" Based on Surrounding Environment
白云追月素
发表于 2024-4-2 09:19:48
230
0
0
According to a recent list released by the US Trademark and Patent Office (USPTO), Apple has obtained a new patent for the Vision Pro, which enhances the "focus mode" based on the dynamic enhancement of the surrounding environment and reduces distractions for wearers. According to the patent description, the "focus mode" on Vision Pro can be dynamically adjusted according to the wearer's surroundings, making the wearer more immersed in the virtual world.
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
You may like
- JD Allianz Equity Transfer Approved: Allianz Insurance Group to Transfer 53.33% Equity of the Company to Allianz China Holdings
- Sanofi: Targeted therapy drug for chronic obstructive pulmonary disease (COPD), Dabitou, approved in China
- Intel Technology is expected to complete $8.5 billion in financing by the end of the year; A total of 109 domestic online games were approved in September
- Johnson&Johnson's drug Zebaike has been approved in China
- Lilly's Alzheimer's disease drug Kisunla approved for sale in the UK
- Lilly's Alzheimer's disease drug Kisunla approved for sale in the UK
- Han Xinyi will take over as CEO of Ant Group in March next year, focusing on the work of Chairman Jing Xiandong
- Ant Group announces that Han Xinyi will take over as CEO Jing Xiandong in March next year, focusing on the work of chairman
- Multiple new indications for Merck drugs approved for market in China
- BeiGene and BeiZeAn are approved for new indications in the United States